Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Share Price History
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
(3)
About
Alivus Life Sciences Ltd.
NSE: ALIVUS
|
BSE: 543322
|
ISIN: INE03Q201024
|
Industry: Pharmaceuticals
|
Expensive Performer
1079.2500
13.50
(
1.27
%)
NSE
Mar 19, 2025
14:13 PM
49.95% Gain from 52W Low
Volume:
38,895
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Alivus Life Sciences Ltd.
22 Jul 2023
1079.25
1.27%
Glenmark Life Sciences (HOLD): Another good quarter; cut to HOLD post rally
Hold:
Alivus Life Sciences Ltd.
by
BOB Capital Markets Ltd.
Target: 620
Recommendation
Target
BOB Capital Markets Ltd.
Strong Q1 with EBITDA/PAT beat of 10%/6% despite slight miss on revenue
Alivus Life Sciences Ltd. has gained
42.06%
in the last 1 Year
More from Alivus Life Sciences Ltd.
Recommended
Market trades higher, Jyoti Structures raises Rs 459.7 crore via a rights issue
Trendlyne Marketwatch |
19 Mar 2025, 02:11PM
Five stocks to buy from analysts this week - March 18, 2025
The Baseline |
18 Mar 2025, 05:17PM
Glenmark Life Sciences: The hived off API business of Glenmark Pharma goes public
|
27 Jul 2021